Introduction/Background Primary debulking surgery still the preferred surgical route and considered a quality indicator for advanced ovarian cancer surgery. However, a significant portion of the patients are not amenable for upfront surgery, and therefore neoadjuvant chemotherapy and interval debulking surgery concept is the best current approach for this group. This study aimed to evaluate the ability of a novel score in prediction of the surgical outcomes at primary debulking surgery for ovarian cancer patients, and based on deciding to pursue on primary surgery or switching to neoadjuvant chemotherapy.

Methodology This observational prospective study was conducted between December 2018 and August 2022. Patients with peritoneal carcinomatosis due to ovarian carcinoma were included. Patients’ clinic, radiologic, and laparoscopic findings were recorded, and anticipated required surgical procedures were determined, and based on Cukurova score was developed. Cytoreduction results, postoperative morbidities, and 90-day mortality were compared between patients according to Cukurova score value and debulking type. Area under curve, sensitivity, specificity, positive predictive, negative predictive and accuracy values of Cukurova score were analzyzed.

Results One hundred fourteen patients were included in the study. Primary debulking surgery was performed in 70% of the cases. Among them, complete cytoreduction (R0) was obtained in 97.3%, and optimal cytoreduction (R1) was achieved in 2.7% of cases with Cukurova score ≤12. A result of no macroscopic residual disease was not succeeded in any of the cases whose Cukurova score was >12, moreover 75% of them ended with nonoptimal surgery. Odds ratio of 90-day mortality was 13.4 (1.5–119.7) for patients with Cukurova score >12 comparing with those with ≤12.

Conclusion Cukurova score is a highly promising model for discriminating advanced ovarian cancer patients to primary debulking surgery or neoadjuvant chemotherapy based on an individualized patient-oriented concept that could weigh surgery-related morbidity and mortality while predicting complete cytoreduction rates.

Disclosures None